NCT01913951View on ClinicalTrials.gov

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

November 22, 2013

Primary Completion Date

December 5, 2016

Study Completion Date

April 29, 2024

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

vosaroxin

Given IV over 10 minutes on Day 1 and 4

DRUG

Azacitidine

Given SC or IV over 15 minutes on days 1-7

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Sunesis Pharmaceuticals

All Listed Sponsors

collaborator

Sunesis Pharmaceuticals

INDUSTRY

lead

Washington University School of Medicine

OTHER